Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%90 PB Ratio is 3.38 as of Sep. 11, 2026, which is 19% above its 10-year median of 2.85. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 784 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks worse than 70.03% on this metric.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's PB Ratio or its related term are showing as below:
SHSE:603087'
s PB Ratio Range Over the Past 10 Years
Min: 1.89 Med: 2.85 Max: 11.31
Current: 3.38
During the past 13 years, Gan and Lee Pharmaceuticals's highest PB Ratio was 11.31. The lowest was 1.89. And the median was 2.85.
SHSE:603087's PB Ratio is ranked worse than 70.03% of 784
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs SHSE:603087: 3.38
During the past 12 months, Gan and Lee Pharmaceuticals's average Book Value Per Share Growth Rate was 7.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 19.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Gan and Lee Pharmaceuticals was 45.50% per year. The lowest was 0.50% per year. And the median was 29.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Gan and Lee Pharmaceuticals PB Ratio Related Terms
Gan and Lee Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603087 vs ISRG, BDX, RMD: PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Gan and Lee Pharmaceuticals (SHSE:603087) has a PB Ratio of 3.38 as of Sep. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is 19% above median its historical median of 2.85. Over the past decade, Gan and Lee Pharmaceuticals' PB Ratio has ranged from 1.89 to 11.31. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #549 out of 784 companies in the Medical Devices & Instruments industry, placing it in the top 70%.
Is Gan and Lee Pharmaceuticals' PB Ratio too high?
Gan and Lee Pharmaceuticals' current PB Ratio of 3.38 is 19% above median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 11.31. The Medical Devices & Instruments industry median PB Ratio is 2.07. Gan and Lee Pharmaceuticals' value of 3.38 is 63.3% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #549 out of 784 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #549 out of 784 companies for PB Ratio. This places Gan and Lee Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.07. Gan and Lee Pharmaceuticals' value of 3.38 is 63.3% above this benchmark. Historically, Gan and Lee Pharmaceuticals' own PB Ratio has ranged from 1.89 to 11.31 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 2.07, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current PB Ratio of 3.38 is 63.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current PB Ratio is 3.38, which is 19% above median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current PB Ratio is 3.38, which is 19% above median its 10-year median of 2.85 and 63.3% above the Medical Devices & Instruments industry median of 2.07. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current PB Ratio is 3.38 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
PB Ratio: 3.38 (19% above median its 10-year median of 2.85)
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
Industry Position: 63.3% above the Medical Devices & Instruments median (#549 of 784)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
